Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Korea Stock Exchange  >  SK Holdings Co., Ltd    A034730   KR7034730002


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

SK : FDA Approves XCOPRI, an Anti-Epileptic Drug from SK Biopharmaceuticals and SK Life Science

11/25/2019 | 08:27am EST

Pangyo - SK Biopharmaceuticals, Co., Ltd., an innovative global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, and its U.S. subsidiary SK Life Science, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adults.

'The approval of XCOPRI will provide clinicians with an effective medication for our patients who are continuing to have focal (partial-onset) seizures,' said Michael Sperling, MD, Professor of Neurology and Director of the Jefferson Comprehensive Epilepsy Center at the Vickie and Jack Farber Institute for Neuroscience - Jefferson Health in Philadelphia, and an investigator in the XCOPRI clinical development program. 'It is very encouraging to see that patients receiving XCOPRI saw significant reductions in frequency of seizures, with some even achieving zero seizures.'

The approval is based on results from two global, randomized, double-blind, placebo-controlled studies and a large, global, multi-center, open-label safety study that enrolled adults with uncontrolled partial-onset seizures, taking one to three concomitant anti-epileptic drug (AEDs). In the randomized studies (Study 013 and Study 017), XCOPRI demonstrated significant reductions in seizure frequency compared to placebo at all doses studied.

'Approximately 3 million adults live with epilepsy in the U.S. and according to the Centers for Disease Control and Prevention (CDC), nearly 60% reported having seizures, even if they took an AED,' said Beth Lewin Dean, Chief Executive Officer of Citizens United for Research in Epilepsy (CURE). 'There is an urgent need to advance research and introduce new treatment options. The FDA approval of XCOPRI for the treatment of partial-onset seizures is a welcome option for the epilepsy community.'

The approval also marks the first time a Korean company has independently brought a compound from discovery to U.S. FDA approval.

'Today's approval is a major step toward our goal of becoming a fully-integrated global pharmaceutical company that can discover, develop and deliver new treatment options in epilepsy and CNS,' said Jeong Woo Cho, PhD, President and CEO of SK Biopharmaceuticals and SK life science. 'We are grateful to the thousands of participants in our trials, clinical investigators, partners in the epilepsy community and our employees for their important contributions in bringing forward this treatment option for adults with partial-onset seizures.'

In Study 013, which included a 6-week titration phase followed by a 6-week maintenance phase, a statistically significant 56% reduction in median seizure frequency was seen with XCOPRI 200 mg/day (n=113) versus a 22% reduction with placebo (n=108). In Study 017, which included a 6-week titration phase followed by a 12-week maintenance phase, patients randomized to XCOPRI 100 mg/day (n=108), 200 mg/day (n=109) or 400 mg/day (n=111) had statistically significant 36%, 55% and 55% reductions in median seizure frequency, respectively, versus a 24% reduction with placebo (n=106). During the maintenance phase of Study 013, a post-hoc analysis showed that 28% of patients receiving XCOPRI had zero seizures, compared with 9% of placebo patients. During the maintenance phase of Study 017, 4% of patients in the XCOPRI 100 mg/day group, 11% of patients in the XCOPRI 200 mg/day group, 21% of patients in the XCOPRI 400 mg/day group and 1% of patients in the placebo group reported zero seizures.

Serious reactions associated with XCOPRI include drug reaction with eosinophilia and systemic symptoms (DRESS), QT shortening, suicidal behavior and ideation, and neurological adverse reactions. The most common (10% and greater than with placebo) treatment-emergent adverse events associated with XCOPRI include somnolence (sleepiness), dizziness, fatigue, diplopia (double vision) and headache.

XCOPRI is expected to be available in the U.S. in the second quarter of 2020, following scheduling review by the DEA, which typically occurs within 90 days of FDA approval. SK life science is committed to supporting patients taking XCOPRI and will introduce a new access program to help patients get started and stay on track with their medicine.

About XCOPRI (cenobamate tablets)

XCOPRI was discovered and developed by SK Biopharmaceuticals and SK life science and is an FDA-approved anti-epileptic drug (AED) for the treatment of partial-onset seizures in adults. XCOPRI is expected to be available in the second quarter of 2020, pending scheduling review by the U.S. Drug Enforcement Administration (DEA). In early 2019, SK Biopharmaceuticals entered into an exclusive licensing agreement with Arvelle Therapeutics GmbH to develop and commercialize XCOPRI in Europe.

While the precise mechanism by which XCOPRI exerts its therapeutic effect is unknown, XCOPRI is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the -aminobutyric acid (GABAA) ion channel.

XCOPRI should be initiated at 12.5 mg once-daily and titrated every two weeks; it will be available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg. XCOPRI can be combined with other AEDs or used alone.

Long-term safety of XCOPRI has been evaluated in the ongoing open-label extensions of the randomized studies and the open-label safety study. Additional clinical trials are investigating XCOPRI in other seizure types.

About Epilepsy

Epilepsy is a common neurological disorder characterized by seizures.1 There are approximately 3 million adults in the U.S. living with epilepsy and approximately 60% have partial-onset seizures, which begin in just one part of the brain.2,3 People with epilepsy are at risk for accidents and other health complications including falling, drowning, depression and sudden unexplained death in epilepsy (SUDEP).3,4 Despite the availability of many antiepileptic therapies, approximately 40% of adults with partial-onset seizures have inadequate control of their seizures, even after treatment with two anti-epileptic drugs (AEDs).5

About SK Biopharmaceuticals, Co., Ltd. and SK Life Science, Inc.

SK Biopharmaceuticals and its U.S. subsidiary SK life science are focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS). Additionally, SK Biopharmaceuticals is focused on early research and development in oncology. Both are part of SK Group, one of the largest conglomerates in Korea.

SK Holdings continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Holdings is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses.

Currently, SK Biopharmaceuticals is conducting basic research for the development of innovative new therapies at its research center in Pangyo, Gyeonggi Province, Korea. SK life science, based in Paramus, New Jersey, is pursuing clinical development and the U.S. commercialization of XCOPRI.

The companies have a pipeline of eight compounds in development for the treatment of CNS disorders including epilepsy, Lennox-Gastaut syndrome and attention-deficit/hyperactivity disorder, among others.


Email: skbp@sk.com

(C) 2019 Electronic News Publishing, source ENP Newswire

All news about SK HOLDINGS CO., LTD
01/08MARKET CHATTER : SK Group to Invest $1.5 Billion in US Hydrogen Fuel Cell Manufa..
01/07MARKET CHATTER : Korea's Commerce, Industry Chamber Set to Tap SK Chairman as Ch..
01/06South Korea's SK Group to invest $1.5 bln in fuel cell maker Plug Power
01/05SK BIOPHARMACEUTICALS : to sell Arvelle Therapeutics stake to Angelini Pharma
2020MARKET CHATTER : South Korea's Big Four Tech Firm Bosses Richer than its Four Ch..
2020WHERE WATER TURNS TO SNOW : S.Korean ultra-cold warehouse prepares to store Pfiz..
2020MARKET CHATTER : SK Holdings Invests $200 Million in Roivant Sciences' Platform ..
2020MARKET CHATTER : SK Holdings Establishes Hydrogen Business Team
2020MARKET CHATTER : SK Group-Led "Happiness Alliance" Now has More than 100 Member ..
2020SK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open Innova..
More news
Sales 2020 84 847 B 77,1 B 77,1 B
Net income 2020 426 B 0,39 B 0,39 B
Net Debt 2020 38 779 B 35,3 B 35,3 B
P/E ratio 2020 49,8x
Yield 2020 1,87%
Capitalization 15 822 B 14 423 M 14 382 M
EV / Sales 2020 187x
EV / Sales 2021 175x
Nbr of Employees 4 264
Free-Float 44,8%
Duration : Period :
SK Holdings Co., Ltd Technical Analysis Chart | A034730 | KR7034730002 | MarketScreener
Technical analysis trends SK HOLDINGS CO., LTD
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 15
Average target price 333 200,00 KRW
Last Close Price 302 500,00 KRW
Spread / Highest target 48,8%
Spread / Average Target 10,1%
Spread / Lowest Target -12,4%
EPS Revisions
Managers and Directors
Tae-Won Chey Chairman & Co-Chief Executive Officer
Dong-Hyun Jang President, Co-Chief Executive Officer & Director
Jung-Ho Park Co-President & Co-Chief Executive Officer
Jae-Ho Yeom Chairman
Eui-Dong Jang Executive Board Member & Head-Finance
Sector and Competitors
1st jan.Capitalization (M$)
SK HOLDINGS CO., LTD25.78%14 590
BP PLC21.37%85 581
NESTE OYJ5.24%58 066